Table 1 Multivariable Cox proportional hazards model of ZNRF3 loss on metastatic relapse, corrected for clinical prognostic factors, adjusted PGA, and IDC-P/CA.

From: Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse

Variable

Level

N

Hazard Ratio

95% Confidence Interval

p-Value

ZNRF3 Loss

     
 

Neutral

298

–

–

–

 

Loss

28

3.53

1.47–8.47

4.72E−03

PSA

Continuous

326

1.05

0.96–1.14

0.31

Gleason Score

     
 

3+3

54

–

–

–

 

3+4

190

4.29

0.53–34.6

0.17

 

4+3

73

9.62

1.15–80.3

0.036

 

4+4 and above

9

5.33

0.31–93.0

0.25

Clinical T Category

     
 

cT1

157

–

–

–

 

cT2a/b

160

1.63

0.68–3.94

0.27

 

cT2c

9

2.47

0.29–21.4

0.41

Adjusted PGA

Continuous

326

1.09

0.47–2.53

0.84

IDC-P/CA

     
 

Absent

222

–

–

–

 

Present

104

1.58

0.67 - 3.57

0.27

  1. The prognostic impact of ZNRF3 loss was evaluated using a multivariable Cox Proportional Hazards model, with pre-treatment PSA, Gleason Score, Clinical T-Category, adjusted PGA (i.e. PGA with chromosome 22 excluded), and IDC-P/CA as co-variates. p-values calculated from a Wald test. Source data are provided as a Source Data file.
Back to article page